Piramal Pharma Solutions and part of Piramal Pharma Ltd. has signed a Memorandum of Understanding (MOU) to solidify its strategic partnership and explore potential collaboration opportunities in ADC development with IntoCell Inc. Pursuant to this non-exclusive and non-binding agreement, IntoCell will explore licensing opportunities for its proprietary drug-linker technologies with Piramal's clients. In exchange, Piramal will offer comprehensive contract research, development, and manufacturing of bioconjugates, including ADCs, to IntoCell and its client base. This partnership enhances Piramal's robust, existing payload-linker and bioconjugation capabilities.
Through this agreement, Piramal can now offer clients a broader range of payload-linkers, and faster bioconjugate development times, thereby improving its service offerings and competitiveness in this specialized field. The licensing agreement centers on IntoCell's proprietary drug-linker technologies, including its OHPAS linker, Duocarmycin based OHPAS-payload, Nexatecan based GGFG-payload. Additionally, this agreement strengthens ADCelerate??, Piramal's rapid, integrated approach to bioconjugate development and manufacture.
Utilizing IntoCell's existing resources allows Piramal to further streamline the path from concept to clinic.
